AbbVie’s Rinvoq, meanwhile ... a follow-up to its 2015 infusion pump Duopa. With a non-surgical, continuous delivery system, the drug has the potential to “significantly expand use” beyond ...

Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...

AbbVie cautions that these forward-looking statements ... It can deliver high levodopa doses similar to the amount provided ...

AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system innovation in the space as drugmakers sought to avoid the common ...

The drug also represents the next generation of AbbVie's Parkinson's therapy offerings and a successor of sorts to the company's Duopa, which launched in 2015. Coverage for Medicare patients is ...

AbbVie also sells a continuous-delivery system for Parkinson's branded as Duopa that pumps a levodopa-carbidopa gel directly into the intestinal tract for 16 hours a day. The FDA recently rejected ...

AbbVie already sells another long-acting treatment called Duopa, which delivers carbidopa and levodopa in an intestinal gel form via a gastric tube and pump, but that requires a surgical procedure ...

AbbVie Inc. discovers, develops ... Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for ...

About AbbVie Inc. and Novo Nordisk A/S AbbVie Inc. discovers ... Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine ...